Cite
HARVARD Citation
Halwani, A. et al. (2022). Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma. Leukemia & lymphoma. 63 (4), pp. 821-833. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Halwani, A. et al. (2022). Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma. Leukemia & lymphoma. 63 (4), pp. 821-833. [Online].